OMER Stock - Omeros Corporation
Unlock GoAI Insights for OMER
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $-1,386,000 | $-1,616,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-169,258,000 | $-164,530,000 | $-163,389,000 | $-173,617,000 | $-156,918,000 |
| Net Income | $-156,815,000 | $-117,813,000 | $47.42M | $-111,413,000 | $-138,061,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.70 | $-1.88 | $0.46 | $3.12 | $-2.41 |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 10th 2025 | H.C. Wainwright | Initiation | Buy | $9 |
| December 23rd 2024 | D. Boral Capital | Initiation | Buy | $36 |
| November 14th 2024 | Rodman & Renshaw | Initiation | Buy | $9 |
| December 8th 2022 | UBS | Downgrade | Neutral | $2← $12 |
| November 8th 2022 | BofA Securities | Downgrade | Underperform | $3← $8 |
| June 8th 2022 | BofA Securities | Downgrade | Neutral | $4← $12 |
Earnings History & Surprises
OMEREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.55 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.58 | $-0.19 | +67.2% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.55 | $-0.53 | +3.6% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.57 | $-0.65 | -14.0% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.78 | $-0.63 | +19.2% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.70 | $-0.64 | +8.6% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-1.14 | $-1.12 | +1.8% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.58 | $-0.74 | -27.6% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.56 | $-0.63 | -12.5% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.62 | $-0.82 | -32.3% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.60 | $-0.70 | -16.7% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.55 | $-0.63 | -14.5% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $-0.57 | $-0.73 | -28.1% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.61 | $-0.87 | -42.6% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.68 | $-0.60 | +11.8% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.74 | $-0.56 | +24.3% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.30 | $-0.37 | -23.3% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.45 | $-0.26 | +42.2% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.50 | $-0.40 | +20.0% | ✓ BEAT |
Q2 2021 | May 10, 2021 | $-0.51 | $-0.50 | +2.0% | ✓ BEAT |
Latest News
D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
📈 PositiveOmeros Closes Asset Purchase And License Agreement With Novo Nordisk For OMS906; Omeros Eligible For Upfront And Near-Term Milestones Up to $340M, of which $240M Was Paid In Cash At Closing, With Omeros Eligible For Up to $2.1B In Milestones And Royalties
📈 PositiveD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
📈 PositiveOmeros Q3 Adj. EPS $(0.34) Beats $(0.45) Estimate
📈 PositiveOmeros shares are trading lower. The company yesterday announced it published a peer-reviewed manuscript in Blood Advances about the survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy treated with narsoplimab across both the pivotal clinical trial and the global expanded access program.
➖ NeutralD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
📈 PositiveOmeros Published Study In "Blood Advances" Shows Narsoplimab Significantly Improves Survival In High-Risk TA-TMA Patients
📈 PositiveNeedham Reiterates Hold on Omerosto Hold
➖ NeutralWBB Securities Reiterates Strong Buy on Omeros, Maintains $45 Price Target
📈 PositiveHC Wainwright & Co. Maintains Buy on Omeros, Raises Price Target to $20
📈 PositiveOmeros shares are trading higher after the company announced Novo Nordisk acquired its global rights to Zaltenibart.
📈 PositiveD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
📈 PositiveNovo Nordisk boosts Omeros with licensing deal worth up to $2.1B
📈 PositiveNovo Nordisk Acquires Global Rights To Zaltenibart From Omeros; Omeros Is Eligible To Receive $340M In Upfront And Near-Term Milestone Payments, Up To A Total Of $2.1B
📈 PositiveD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
📈 PositiveOmeros Corp. Reports Survival Outcomes With Narsoplimab In TA-TMA Patients In Peer-Reviewed Study Published In American Journal Of Hematology
📈 PositiveOmeros Posts 2,652 Percent Sales Jump
📈 PositiveOmeros rises after pricing ~$22M stock offering
📈 PositiveOmeros stock rises after pricing of $22 million registered direct offering
📈 PositiveFrequently Asked Questions about OMER
What is OMER's current stock price?
What is the analyst price target for OMER?
What sector is Omeros Corporation in?
What is OMER's market cap?
Does OMER pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OMER for comparison